Literature DB >> 17467547

Cystic fibrosis: a review of epidemiology and pathobiology.

Steven D Strausbaugh1, Pamela B Davis.   

Abstract

Improvements in outcomes for patients who have cystic fibrosis (CF) have been striking in the last 30 years. Median survival now approaches the fifth decade of life. Advances in the understanding of the basic defect and the pathobiology of CF have led to new treatments, some of which have undoubtedly contributed to this success. Improved understanding of the basic defect and the acquisition and maintenance of epidemiologic resources for the CF population in the United States have allowed us to determine predictors of survival and identify genetic, environmental, and therapeutic factors that may influence it. This article reviews some of the key epidemiologic and pathobiologic factors discovered thus far.

Entities:  

Mesh:

Year:  2007        PMID: 17467547     DOI: 10.1016/j.ccm.2007.02.011

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  58 in total

1.  Dynamic regression with recurrent events.

Authors:  J E Soh; Yijian Huang
Journal:  Biometrics       Date:  2019-09-12       Impact factor: 2.571

Review 2.  Prospects for epigenetic epidemiology.

Authors:  Debra L Foley; Jeffrey M Craig; Ruth Morley; Craig A Olsson; Craig J Olsson; Terence Dwyer; Katherine Smith; Richard Saffery
Journal:  Am J Epidemiol       Date:  2009-01-12       Impact factor: 4.897

Review 3.  Dental caries prevalence in children and adolescents with cystic fibrosis: a qualitative systematic review and recommendations for future research.

Authors:  Donald L Chi
Journal:  Int J Paediatr Dent       Date:  2013-06-12       Impact factor: 3.455

4.  The Pseudomonas toxin pyocyanin inhibits the dual oxidase-based antimicrobial system as it imposes oxidative stress on airway epithelial cells.

Authors:  Balázs Rada; Kristen Lekstrom; Sorin Damian; Corinne Dupuy; Thomas L Leto
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

5.  Initial interrogation, confirmation and fine mapping of modifying genes: STAT3, IL1B and IFNGR1 determine cystic fibrosis disease manifestation.

Authors:  Heike Labenski; Silke Hedtfeld; Tim Becker; Burkhard Tümmler; Frauke Stanke
Journal:  Eur J Hum Genet       Date:  2011-07-06       Impact factor: 4.246

6.  The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin.

Authors:  Manuele Furnari; Alessandra De Alessandri; Federico Cresta; Maria Haupt; Marta Bassi; Angela Calvi; Riccardo Haupt; Giorgia Bodini; Iftikhar Ahmed; Francesca Bagnasco; Edoardo Giovanni Giannini; Rosaria Casciaro
Journal:  J Gastroenterol       Date:  2018-09-19       Impact factor: 7.527

7.  Physical Characterization of 1,3-dipropyl-8-cyclopentylxanthine (CPX).

Authors:  Timothy McPherson; Rahul V Manek; William Kolling; Sihui Long; Tonglei Li
Journal:  AAPS PharmSciTech       Date:  2010-05-04       Impact factor: 3.246

Review 8.  Hepatic Manifestations of Cystic Fibrosis.

Authors:  Sasan Sakiani; David E Kleiner; Theo Heller; Christopher Koh
Journal:  Clin Liver Dis       Date:  2019-02-21       Impact factor: 6.126

9.  Societal Implications of Health Insurance Coverage for Medically Necessary Services in the U.S. Transgender Population: A Cost-Effectiveness Analysis.

Authors:  William V Padula; Shiona Heru; Jonathan D Campbell
Journal:  J Gen Intern Med       Date:  2015-10-19       Impact factor: 5.128

10.  Changing incidence of cystic fibrosis in Wisconsin, USA.

Authors:  Katelyn Parker-McGill; Melodee Nugent; Rachel Bersie; Gary Hoffman; Michael Rock; Mei Baker; Philip M Farrell; Pippa Simpson; Hara Levy
Journal:  Pediatr Pulmonol       Date:  2015-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.